CureVac GmbH
Paul-Ehrlich-Str. 15
Tübingen
72076
Germany
Tel: 49-7071-92053-0
Fax: 49-7071-92053-11
Website: http://www.curevac.de/
143 articles with CureVac GmbH
-
GlaxoSmithKline exceeded expectations for its first-quarter sales and earnings forecasts. This was largely driven by its sales of Xevudy, an antibody treatment against COVID-19 it developed with Vir Biotechnology, and its Shingrix vaccine against shingles.
-
CureVac and GSK Enter into Pandemic Preparedness Contract with German Government
4/11/2022
CureVac N.V. and GSK today announced that they have entered into a contract with the German federal government to supply mRNA vaccines within a broader tender for pandemic preparedness in Germany.
-
The FDA is looking at revising the current vaccine strategy and emphasizing that individuals need to consider their own risk tolerance. For that and more, continue reading.
-
It was a particularly busy week for clinical trial announcements. Let's take a look.
-
CureVac Establishes Fully-Owned Company Dedicated to Advancing The RNA Printer(R)
3/1/2022
CureVac RNA today announced that it has established CureVac RNA Printer GmbH, a fully-owned CureVac company to advance The RNA Printer(R).
-
Five Top CEOs to Watch in 2022
2/23/2022
Several CEOs have stood out from their peers throughout the past year, winning recognition from the Healthcare Technology Report. BioSpace looks at five of these leaders. -
dievini and Related Parties Underline Their Strong Commitment as Shareholders of Curevac N.V. And Do No Longer Plan to Sell Shares to The Public
2/22/2022
dievini Hopp BioTech holding GmbH & Co. KG (dievini), DH-LT-Investments GmbH and Dietmar Hopp today announced that they no longer plan to sell some of the CureVac common shares (NASDAQ: CVAC) to the public, as reported in a 13-D filing with the U.S. Securities and Exchange Commission (SEC) on 13 January 2022.
-
dievini and the Federal Republic of Germany Amend Shareholders’ Agreement Regarding Investments in CureVac N.V.
1/13/2022
dievini and the Federal Republic of Germany announced the signing of a supplement to the shareholders' agreement between Kreditanstalt für Wiederaufbau and the investment company dievini Hopp BioTech holding GmbH & Co. KG, DH-LT-Investments GmbH, and Dietmar Hopp related to their common shares in CureVac N.V.
-
According to the Environmental Litigation Group, P.C., approximately 37.5% of all occupational lung cancer cases are related to occupational asbestos exposure.
-
Two years into the COVID-19 pandemic, countries are reporting the fourth wave of rising cases, driven mainly by the Delta variant, although Omicron has everybody concerned. Here’s a look.
-
CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2021 and Provides Business Update
11/19/2021
CureVac N.V., a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid, announced financial results for the third quarter and first nine months of 2021 and provided a business update.
-
CureVac Publishes in Nature Preclinical Data of Second-Generation COVID-19 Candidate, CV2CoV, Demonstrating Comparable Antibody Levels to Licensed mRNA Vaccine
11/18/2021
CureVac N.V., a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid, announced the online publication of the extended preclinical study of the second-generation vaccine candidate, CV2CoV, jointly developed with GSK, in the journal Nature.
-
Clinical Catch-Up: November 8-12
11/15/2021
It was another busy week for clinical trial news. Here’s a look. -
CureVac to Shift Focus of COVID-19 Vaccine Development to Second-Generation mRNA Technology
10/12/2021
CureVac N.V. today announced the strategic decision to focus its COVID-19 vaccine development towards the development of second-generation mRNA vaccine candidates in collaboration with GSK and to withdraw its first-generation COVID-19 vaccine candidate, CVnCoV, from the current approval process with the European Medicines Agency (EMA).
-
Teamed up with pharma giant GlaxoSmithKline, CureVac is now focusing on a more promising target – second-generation mRNA vaccines.
-
CureVac Streamlines European Network for mRNA Product Manufacturing
9/14/2021
CureVac N.V., a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid, announced its strategic decision to adjust the long-term footprint of the external European manufacturing network for its mRNA product pipeline.
-
CureVac NV is downsizing its European mRNA production network due to decreased demand for vaccines after the first wave of vaccinations.
-
CureVac's CVnCoV Phase 2b/3 Study Data Published in Preprints with The Lancet
8/31/2021
CureVac N.V., a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid, announced the publication of its pivotal Phase 2b/3 primary data of CVnCoV, its first-generation COVID-19 vaccine candidate, in Preprints with The Lancet.
-
The research underlines the progress being made in messenger RNA approaches, as spotlighted by the success of the mRNA vaccines against COVID-19.